Superbugs: Antibiotic Resistance & The Effects on Modern Healthcare

Superbugs: Antibiotic Resistance & The Effects on Modern Healthcare


In the realm of medical science, where each discovery paves the way for a healthier future, there exist silent adversaries that continually threaten the health of millions. Termed ‘superbugs’, these resilient pathogens not only pose significant threats to individual health but also burden the healthcare system with enormous costs. Below, we will delve deep into the world of superbugs, outlining their nature, dangers, and the urgent need for innovative solutions.

What are Superbugs?

‘Superbug’ is a colloquial term for bacteria that have developed resistance to multiple types of antibiotics. These microorganisms are tougher and harder to kill, making infections caused by them difficult to treat. Their resistance is typically attributed to the misuse or overuse of antibiotics, which allows only the most resilient bacteria to survive and multiply.

Common Types of Superbugs

Staphylococcus aureus

Staphylococcus aureus, commonly referred to as “staph,” is a gram-positive bacterium that can be found on the skin or in the nasal passages of about one-third of the population. While often harmless, it can cause a range of illnesses from minor skin infections to severe diseases like pneumonia, meningitis, and septicemia. Methicillin-resistant Staphylococcus aureus (MRSA) is a type of staph bacteria that has become resistant to many commonly used antibiotics. MRSA can lead to severe health complications and is notably more challenging to treat.

Acinetobacter baumannii

Acinetobacter baumannii’s resilience allows it to persist on surfaces for extended periods. This trait poses a significant challenge in medical environments, as it can lead to the contamination of communal medical tools and hospital areas. Intensive care units often witness the bulk of infections caused by A. baumannii, resulting in conditions like pneumonia, infections in the bloodstream, and issues in the urinary tract. A concerning aspect is that a majority of A. baumannii strains found in hospitals display resistance to antibiotics from the carbapenem class, a group frequently prescribed for such infections. Alarmingly, some strains show resistance to almost every antibiotic available. In 2017, the CDC reported that this problematic microorganism was responsible for around 8,500 infections in patients admitted to hospitals, contributing to an estimated 700 fatalities.


Utilizing the same cutting board for preparing raw chicken and slicing vegetables can pave the way for an uncomfortable bout with Campylobacter. The bacterium primarily transmits to humans via undercooked chicken, untreated milk, and other tainted food or water sources. Even touching farm animals or domestic pets can be a potential source of transmission. According to the CDC, each year sees approximately 448,400 cases of antibiotic-resistant Campylobacter, with the proportion of these drug-resistant infections showing an upward trend.

Candida auris

In healthcare establishments, one possible infection patients might encounter is from Candida auris (C. auris). This particular yeast, a form of fungus, is known for both its capacity to induce serious ailments and its propensity to transmit quickly, occasionally resulting in hospital outbreaks. A concerning aspect of C. auris is its frequent resistance to antifungal agents, rendering many standard treatments ineffective against it.

Clostridioides difficile

C. diff, formally recognized as Clostridioides difficile or C. difficile, is a bacterium responsible for triggering diarrhea and inflaming the colon, a condition known as colitis. Every year in the U.S., it’s believed to instigate nearly half a million infections. Roughly 1 out of every 6 individuals who contract C. diff face a recurrence within the following 2 to 8 weeks. For those aged over 65 who are diagnosed with a C. diff infection acquired from a healthcare setting, approximately 1 in 11 succumb within a month’s time.


Enterobacteriaceae is a large family of Gram-negative bacteria that primarily inhabit the intestines of humans and other animals. Some members of this family can exist outside the intestines, in the environment or on various surfaces. While many members of the Enterobacteriaceae family are harmless and even beneficial, some can be pathogenic, causing a variety of diseases. Some well-known members and related diseases include:

  1. Escherichia coli (E. coli): While many strains are harmless and are part of the normal gut flora, some can cause diseases ranging from urinary tract infections to severe food poisoning.
  2. Salmonella: Causes salmonellosis, a type of food poisoning.
  3. Shigella: Causes shigellosis or bacillary dysentery.
  4. Klebsiella pneumoniae: Can cause pneumonia, bloodstream infections, and other conditions.
  5. Enterobacter: Associated with various infections, including those in the respiratory and urinary tracts.
  6. Yersinia pestis: The causative agent of plague.

Furthermore, a major concern with some Enterobacteriaceae is their ability to acquire resistance to antibiotics. In particular, the emergence of carbapenem-resistant Enterobacteriaceae (CRE) is a significant public health concern, as these bacteria are resistant to many of the commonly used antibiotics, making infections difficult to treat.


Bacteria from the Enterococcus genus pose a significant threat to individuals in medical environments, particularly those with extended hospital stays, organ transplant recipients, or those admitted to intensive care units. These bacteria can be the culprits behind infections in the bloodstream, surgical areas, and urinary tract. Alarmingly, about 30% of enterococcal infections acquired in healthcare settings demonstrate resistance to the antibiotic vancomycin. This strain, known as vancomycin-resistant enterococci (VRE), is also showing increased resistance to other antibiotics. This trend suggests that the few remaining treatments for VRE might become even less effective over time.


Shigella is a genus of gram-negative bacteria that causes shigellosis, a diarrheal disease in humans. The bacteria are transmitted primarily through contaminated food or water and by direct person-to-person contact. Infection with Shigella typically results in symptoms like diarrhea (which can be bloody), fever, and stomach cramps. While most people recover from the illness without treatment, severe cases may require antibiotics. Proper hand hygiene is crucial for prevention.

Pseudomonas aeruginosa

Pseudomonas aeruginosa is a gram-negative bacterium commonly found in various environments, such as soil, water, and even on human skin. It’s known for its metabolic versatility and ability to thrive in a wide range of conditions. In healthcare settings, it can cause severe infections, especially in immunocompromised individuals. Infections can range from respiratory to urinary tract infections. Notably, P. aeruginosa is often resistant to many common antibiotics, making effective treatment very challenging.

Streptococcus pneumoniae

Streptococcus pneumoniae, which is often referred to simply as “pneumococcus,” is a gram-positive bacterium that is primarily known for causing pneumonia. Besides pneumonia, it can also lead to other serious infections like meningitis and otitis media (ear infections). Vaccines are available and recommended for certain age groups and individuals with specific medical conditions to prevent pneumococcal infections.

Superbugs & HAIs (Healthcare-Associated Infections)

HAIs are infections acquired while receiving medical care. Superbugs are a predominant cause of HAIs, given their prevalence in healthcare settings where antibiotics are heavily used. Surfaces, medical devices, and even healthcare workers can unwittingly become carriers, transmitting these pathogens to patients. For those already in compromised health, an HAI can prove fatal.

The Dangers & Health Risks of Superbugs

Treatment Difficulties: As superbugs resist standard antibiotic treatments, infections can persist, leading to prolonged illness.

Severe Complications: Resistant infections can escalate to life-threatening conditions like sepsis or organ failure.

Spread Potential: Superbugs can spread to others, putting more people at risk.

Limited Therapeutic Options: Fewer effective antibiotics mean limited treatment choices, especially for critical cases.

The Economic Strain of Superbugs on Healthcare

The rise of superbugs incurs significant economic costs to healthcare both in the US and globally. In the US alone, antibiotic-resistant infections account for over $20 billion in direct healthcare costs annually, with an additional $35 billion lost due to reduced productivity. Globally, this figure reaches hundreds of billions. These numbers don’t just reflect treatment costs but also the extended hospital stays, the development of new drugs, and loss of life.

Why do ABR (Antibiotic Resistance) Treatments Fail?

Overprescription: Antibiotics are often unnecessarily prescribed, leading to increased resistance.

Incomplete Treatment: Patients not completing their antibiotic course can leave resilient bacteria behind.

Livestock & Agriculture: Excessive use of antibiotics in livestock can introduce resistant strains into the human food chain.

Lack of New Drugs: Developing new antibiotics isn’t lucrative for pharmaceutical companies, leading to a scarcity of new drugs.

The Need for Innovative Infection Prevention Treatments

As superbugs evolve, so must our approach to tackling them. The healthcare community is recognizing the potential of advanced topical antibiotics like Vitastem Ultra. Here’s why:

Targeted Action: Topical antibiotics act directly at the site of infection, reducing the chances of resistance.

Fewer Side Effects: They often present fewer systemic side effects compared to oral antibiotics or injections.

Infection Protection: New & innovative topical antibiotics like Vitastem Ultra not only treat but also offer protective barriers against microbial invasion.

Reduced HAIs: Effective topical solutions can significantly decrease the risk of HAIs, benefiting both patients and healthcare systems.

In conclusion, the battle against superbugs demands a multi-pronged approach. While public education and antibiotic stewardship play critical roles, innovative solutions like advanced topical antibiotics are the frontiers of hope in this crucial fight to stop the spread of superbugs. The global community must unite in its efforts to curb the rise of these resilient adversaries, safeguarding the health of future generations.